tiprankstipranks
Advertisement

ISMD - ETF AI Analysis

Compare

Top Page

ISMD

Inspire Small/Mid Cap Impact ETF (ISMD)

Rating:64Neutral
Price Target:
ISMD’s rating suggests it is a decent but not standout option among small- and mid-cap impact ETFs, with a mix of strengths and weaknesses in its holdings. Strong contributors like TTM Technologies, which shows solid financial performance and positive momentum, help support the fund’s quality, while weaker names such as Agilon Health and Kopin, both facing profitability and cash flow challenges, weigh on the overall assessment. The main risk is that many holdings struggle with negative or pressured profitability, making the fund sensitive to setbacks in smaller, financially weaker companies.
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and in recent months, indicating positive momentum.
Broad Sector Diversification
Holdings are spread across many sectors like industrials, technology, financials, and health care, which helps reduce the impact if one industry struggles.
Multiple Strong-Performing Holdings
Several top positions, such as Avis Budget and Aehr Test Systems, have delivered strong year-to-date results that support the fund’s overall performance.
Negative Factors
Higher-Than-Average Expense Ratio
The fund’s expense ratio is on the higher side for an ETF, which means more of your returns go toward fees each year.
Heavy U.S. Concentration
With nearly all assets invested in U.S. companies, the fund offers little geographic diversification and is highly tied to the U.S. market.
Small Individual Position Sizes
Each top holding makes up only a small slice of the portfolio, so even strong-performing stocks may have a limited impact on overall returns.

ISMD vs. SPDR S&P 500 ETF (SPY)

ISMD Summary

The Inspire Small/Mid Cap Impact ETF (ISMD) tracks the Inspire Small/Mid Cap Impact Equal Weight Index and focuses on U.S. small and mid-sized companies that meet specific biblical and ethical standards. It spreads investments across many sectors, including industrials, technology, and financials, and holds well-known names like Avis Budget and Iridium Communications. Someone might invest in ISMD to seek long-term growth from smaller, fast-moving companies while aligning their money with their values and gaining diversification beyond large caps. A key risk is that smaller-company stocks can be more volatile and can go up and down more sharply than the overall market.
How much will it cost me?The Inspire Small/Mid Cap Impact ETF (ISMD) has an expense ratio of 0.57%, which means you’ll pay $5.70 per year for every $1,000 invested. This is higher than average for ETFs because it is actively managed and focuses on ethical investing, which involves more research and selection processes. While the cost is higher, it reflects the fund's commitment to aligning investments with specific moral and ethical standards.
What would affect this ETF?The Inspire Small/Mid Cap Impact ETF (ISMD) could benefit from growth in innovative sectors like technology and health care, as well as increased interest in ethical investing. However, it may face challenges from economic slowdowns that disproportionately affect small and mid-cap companies, as well as potential regulatory changes impacting industries like energy and financials. Its focus on U.S.-based firms also makes it sensitive to domestic economic conditions and interest rate fluctuations.

ISMD Top 10 Holdings

ISMD’s story is all about U.S. small and mid-cap names, with a tilt toward tech and industrials rather than the usual mega-cap stars. On the brighter side, Agilon Health has been rising and helping to pull the fund forward, while MaxLinear and Penguin Solutions are also quietly adding some steady tech-driven lift. But several smaller tech and health names like Kopin and Aehr Test Systems are still lagging, acting more like weights on the portfolio. Overall, performance feels like a mixed bag in a diversified, impact-focused U.S. sandbox.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Agilon Health1.18%$3.56M$1.54B66.27%
42
Neutral
Maxlinear1.01%$3.04M$8.32B715.89%
60
Neutral
Aehr Test Systems0.46%$1.40M$2.90B867.82%
55
Neutral
Penguin Solutions0.44%$1.34M$2.83B214.36%
61
Neutral
Kopin0.43%$1.31M$1.04B346.09%
48
Neutral
Ceva0.35%$1.07M$1.11B113.11%
52
Neutral
Westrock Coffee0.35%$1.05M$783.39M16.72%
49
Neutral
Vishay Intertechnology0.34%$1.01M$7.08B269.94%
55
Neutral
Ranpak Holdings0.32%$958.84K$590.26M107.21%
53
Neutral
Hudson Pacific Properties0.32%$950.35K$664.30M-7.99%
46
Neutral

ISMD Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
43.59
Positive
100DMA
42.44
Positive
200DMA
40.38
Positive
Market Momentum
MACD
0.92
Negative
RSI
67.89
Neutral
STOCH
86.01
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ISMD, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 45.62, equal to the 50-day MA of 43.59, and equal to the 200-day MA of 40.38, indicating a bullish trend. The MACD of 0.92 indicates Negative momentum. The RSI at 67.89 is Neutral, neither overbought nor oversold. The STOCH value of 86.01 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ISMD.

ISMD Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$319.48M0.53%
64
Neutral
$761.19M0.75%
68
Neutral
$757.27M0.62%
65
Neutral
$483.62M0.75%
69
Neutral
$333.53M0.49%
68
Neutral
$257.74M0.55%
69
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ISMD
Inspire Small/Mid Cap Impact ETF
47.05
12.89
37.73%
RSMC
Rockefeller U.S. Small-Mid Cap ETF
MSSM
Morgan Stanley Pathway Small-Mid Cap Equity ETF
GRNJ
Fundstrat Granny Shots US Small- & Mid-Cap ETF
SMOT
VanEck Morningstar SMID Moat ETF
SMIZ
Zacks Small/Mid Cap ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement